Skip to main content
. 2019 Oct 18;70(11):2423–2427. doi: 10.1093/cid/ciz846

Table 1. .

Characteristics of Patients With Acute Gastroenteritis (AGE) and Associations With Accurate AGE Coding and Sensitivity Estimates, by Surveillance Platform

Demographics NVSN (N = 13 916a) SUPERNOVA (N = 635a)
With AGE Code (n = 7572), n (%) Without AGE Code (n = 6344), n (%) aORb (95% CI) With AGE Code (n = 368), n (%) Without AGE Code (n = 267), n (%) aORc (95% CI)
Male 4166 (55.0) 3325 (52.4) 340 (92.4) 243 (91.0)
Female 3406 (45.0) 3019 (47.6) 28 (7.6) 24 (9.0)
Median aged (25th IQR, 75th IQR) 18 (9, 31) 18 (9, 33) 1.01 (1.01, 1.02) 63 (53, 70) 64 (55, 71)
Ethnicity n = 7563 n = 6337 n = 367 n = 267
 Non-Hispanic 4468 (59.1) 4299 (67.8) 324 (88.3) 221 (82.8)
 Hispanic 3095 (40.9) 2038 (32.2) 43 (11.7) 46 (17.2)
Race n = 6374 n = 5935 n = 358 n = 257
 White 3148 (46.8) 2606 (43.9) 182 (50.8) 119 (46.3)
 Black 2474 (36.7) 2381 (40.1) 163 (45.5) 126 (49.0)
 Asian/NH/PI 183 (2.7) 121 (2.0) 2 (0.6) 1 (0.4)
 AI/AN 14 (0.2) 11 (0.2) 1 (0.3) 1 (0.4)
 Other 915 (13.6) 816 (13.8) 10 (2.8) 10 (3.9)
Setting
 Inpatient 1692 (22.4) 1162 (18.3 Ref 322 (87.5) 252 (94.4) Ref
 ED 5880 (77.7) 5182 (81.7) 0.81 (0.73, 0.90) 46 (12.5) 15 (5.6) 2.24 (1.16, 4.32)
AGE symptoms documented n = 7564 n = 6324
 Diarrhea with or without vomiting Ref 357 (97.0) 228 (86.0) Ref
 Vomiting alone 763 (10.1) 3408 (53.9) 0.08 (0.07, 0.09) 11 (3.0) 37 (14.0) 0.21 (0.10, 0.42)
Immunocompromising condition presente NA NA 85 (23.1) 53(19.9)
Severe AGEf n = 6621 n = 5658 NA NA
 Yes 3508 (53.0) 1796 (31.8) NA NA
Siteg
 1 1020 (13.5) 1389 (21.9) Ref 72 (19.6) 32 (12.0) Ref
 2 360 (4.8) 754 (11.9) 0.58 (0.48, 0.69) 26 (7.1) 38 (14.2) 0.30 (0.15, 0.61)
 3 1190 (15.7) 1309 (20.6) 1.31 (1.14, 1.51) 221 (60.1) 129 (48.3) 0.68 (0.41, 1.12)
 4 331 (4.4) 220 (3.5) 2.37 (1.85, 3.00) 49 (13.3) 68 (25.5) 0.35 (0.20, 0.63)
 5 1855 (24.5) 943 (14.9) 2.75 (2.40, 3.15)
 6 1564 (20.7) 1247 (19.7) 1.88 (1.63, 2.17)
 7 1252 (16.5) 482 (7.6) 4.08 (3.36, 5.00)
Surveillance yearh
 2011 1225 (16.2) 1105 (17.4) Ref NA NA
 2012 1803 (23.8) 1437 (22.7) 1.05 (0.91, 1.20) NA NA
 2013 1822 (24.1) 1496 (23.6) 1.27 (1.10, 1.45) NA NA
 2014 1916 (25.3) 1471 (23.2) 1.26 (1.09, 1.44) NA NA
 2015 (incomplete) 806 (10.6) 835 (13.2) 1.11 (0.94, 1.30) NA NA
 2016 NA NA 306 (83.2) 259 (63.3)
 2017 (incomplete) NA NA 62 (16.9) 150 (36.7)

All crude ORs and year-specific aORs are provided in Supplementary Table 4.Abbrevations: AGE, acute gastroenteritis; AI/AN, American Indian/Alaska Native; aOR, adjusted odds ratio; CI, confidence interval; ED, emergency department; IQR, interquartile range; NA, not applicable; NH/PI, Native Hawaiian/Pacific Islander; NVSN, New Vaccine Surveillance Network; Ref, reference; SUPERNOVA, Surveillance Platform for Enteric and Respiratory Infections in the Veterans Affairs Population.

aUnless otherwise specified.

bNVSN model adjusted for age, sex, race, ethnicity, year, site, healthcare setting (inpatient vs ED visit), presence of vomiting without diarrhea, and severe AGE.

cSUPERNOVA model adjusted for age, sex, race, ethnicity, site, healthcare setting, and presence of vomiting without diarrhea.

dAge in months for NVSN and age in years for SUPERNOVA.

eImmunocompromising condition present defined as organ transplant, cancer, HIV, and immunosuppressive therapy

fSevere AGE defined as modified Vesikari score ≥11 [15].

gFour SUPERNOVA sites were included in the study: Atlanta VA Medical Center, James J. Peters VA Medical Center, VA Greater Los Angeles Health System (Los Angeles, California), and the Michael E. DeBakey VA Medical Center (Houston, Texas).

hSurveillance year is 1 December–30 November for NVSN and 1 December–30 September for SUPERNOVA.